Coloplast Revenue vs. Return On Asset
Coloplast A Return On Asset vs. Revenue Fundamental Analysis
Peer comparison models estimate Coloplast's intrinsic positioning within its sector. Coloplast A is rated below average in revenue among leading competitors. It ranks first in return on asset among leading competitors . At 131,732,788,798 , Coloplast A's Revenue-to-Return On Asset multiple reflects the spread between these metrics. Coloplast is evaluated using peer multiple analysis when discounted cash flow models are impractical.Coloplast Revenue vs. Competition
Coloplast A is rated below average in revenue among leading competitors. Market size based on revenue of Medical Instruments & Supplies industry is currently estimated at about 2.77 Trillion. Coloplast maintains roughly 22.58 Billion in revenue contributing less than 1% to all equities under Medical Instruments & Supplies space.
Coloplast Return On Asset vs. Revenue
Revenue is income that a firm generates from business activities such as rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Coloplast |
| = | 22.58 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Assets (ROA) measures how efficiently a company generates profit relative to its total asset base. It is calculated by dividing net income by total assets and reflects management's effectiveness at deploying capital across the business. ROA is particularly useful for comparing companies within the same industry, since asset intensity varies widely across sectors.
Coloplast |
| = | 0.17 |
A higher ROA indicates that each dollar of assets produces more income, which generally signals operational efficiency. Asset-heavy industries such as banking, utilities, and manufacturing tend to have lower ROAs than asset-light businesses like software or professional services. When ROA is low, it may indicate either underperforming operations or a capital-intensive business model that requires ongoing investment to sustain revenue.
Coloplast Return On Asset Comparison
Coloplast is currently under evaluation in return on asset among leading competitors.
Coloplast Profitability Projections
A key trait of a strong company is its ability to earn a profit, and for Coloplast investors this matters a lot. A falling profit trend for Coloplast can signal weak results and may point to future losses. Coloplast currently maintains a profit margin of 19.7%. When profits improve despite flat or falling revenue, it shows strong cost control. The operating margin stands at 30.0% while return on equity is 75.1%. The data below helps investors judge the staying power of Coloplast's current profit levels. Recent net income of 4.71 B reflects the bottom-line result of these profitability dynamics.
Coloplast AS engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast is traded on OTC Exchange in the United States.
Coloplast Profitability Driver Comparison
Profitability drivers for Coloplast are the factors with the greatest impact on its earnings and margins. Unexpected events such as policy changes, commodity shocks, or downturns can alter Coloplast's profit outlook. Investors who understand Coloplast's key profit drivers can better assess the sustainability of its earnings.
Earnings per Share Projection vs Actual
Use Coloplast in pair-trading
A pair strategy built around Coloplast A is useful when investors want to reduce directional market exposure while still expressing a relative-value idea. This framework is most useful when investors want to hedge directional moves caused by sector headlines or broad market pressure.
Coloplast Pair Trading
Coloplast A Pair Trading Analysis
Investors who sell Coloplast at a loss must wait 30 days before repurchasing to avoid wash-sale rules. The key is finding instruments that track Coloplast A closely enough to maintain equivalent risk. The correlation table below shows which instruments historically move in lockstep with Coloplast A.
A correlation of +1 between Coloplast and another asset means they move in perfect lockstep. A correlation near zero implies that Coloplast provides genuine diversification benefits. Negative correlation assets provide natural hedges against Coloplast positions in a diversified portfolio.
Using Correlation analysis with pair analysis helps develop hedging context around Coloplast. The analysis can be scoped to sector peers or extended to a wider stock universe.Use Investing Themes to Complement your Coloplast position
With 24.94 Billion market cap in the Medical Instruments & Supplies industry, Coloplast A works well as a mid-cap core holding around which broader thematic baskets can be built. Coloplast A mid-cap scale (24.94 Billion) within Medical Instruments & Supplies helps compare substitutes, complements, and diversifiers that strengthen the overall Healthcare allocation.
Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 42 constituents at this time.
Whether used as a passive allocation or an active trading idea, the Large Value Funds Theme provides a structured starting point for portfolio construction.
| View All Next | Launch |
More Resources for Coloplast Pink Sheet Analysis
Other Information on Investing in Coloplast Pink Sheet
The projection framework for Coloplast A is built on historical financial statement data. The income statement, balance sheet, and cash flow report form the analytical core.